Meyka Pro banner
Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) AI-Powered Stock Analysis

See how Adaptive Biotechnologies Corporation scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

ADPTNASDAQ
HealthcareBiotechnology
$22.27
$0.04(0.18%)
U.S. Market opens in 63h 26m

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) AI-Powered Stock Analysis

See how Adaptive Biotechnologies Corporation scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Stock Overall Grade

Adaptive Biotechnologies Corporation's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Adaptive Biotechnologies Corporation's overall NASDAQ stock rating.

Forecast

A

Score

84/100

Financial Growth

C

Score

40/100

Fundamental Growth

C+

Score

51/100

Key Ratios

C+

Score

52/100

Sector Comparison

A

Score

80/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

97/100

Analyst Consensus

B+

Score

75/100

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) AI-Powered Stock Analysis

On the NASDAQ, ADPT demonstrates Good performance with an overall Forecast Score of 84/100 (A), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (52/100, C+) and Sector Comparison (80/100, A) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (75/100, B+) suggests High divergence in outlook.

(NASDAQ: ADPT) Component Analysis Explained

Understand the key factors behind each Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions